Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.
Patel A, Batra U, Prasad KT, Dabkara D, Ghosh J, Sharma M, Singh N, Suresh P, Jain P, Malik PS, Choudhary P, Ganguly S, Khurana S, Ms S, Bothra S, Muthu V, Biswas B.
Patel A, et al. Among authors: ms s.
Curr Probl Cancer. 2020 Jun;44(3):100571. doi: 10.1016/j.currproblcancer.2020.100571. Epub 2020 Mar 17.
Curr Probl Cancer. 2020.
PMID: 32234264
BACKGROUND: Anaplastic lymphoma kinase (ALK) rearranged metastatic non-small cell lung cancer (NSCLC) comprises 5%-7% of all lung cancer and carries a good prognosis with available ALK-inhibitors. Majority of registration trials in ALK-inhibitors did not include Indian pat …
BACKGROUND: Anaplastic lymphoma kinase (ALK) rearranged metastatic non-small cell lung cancer (NSCLC) comprises 5%-7% of all lung cancer and …